Today: 27 February 2026
Subscribe
Browse Category

NASDAQ:EXAS 19 November 2025 - 2 February 2026

Abbott (ABT) stock price steadies after Barclays trims target; Exact Sciences vote is next key date

Abbott (ABT) stock price steadies after Barclays trims target; Exact Sciences vote is next key date

Abbott Laboratories shares edged up 0.1% to $109.43 after Barclays cut its price target to $142 but kept an Overweight rating. Nutrition sales fell 8.9% last quarter, and diagnostics dropped 2.5%. Exact Sciences shareholders will vote February 20 on Abbott’s planned $23 billion takeover. The deal is expected to close in the second quarter of 2026.
2 February 2026
···
Abbott stock rebounds as Exact Sciences vote nears after broker upgrade

Abbott stock rebounds as Exact Sciences vote nears after broker upgrade

Abbott Laboratories shares rose 2.6% to $108.89 Friday after missing revenue targets and guiding first-quarter adjusted EPS below analyst estimates. Freedom Capital Markets upgraded the stock to “buy” but cut its price target. Abbott expects to close its $23 billion Exact Sciences acquisition by Q2 2026. Exact Sciences shareholders will vote on the merger Feb. 20.
30 January 2026
···
Abbott stock price steadies near a 52-week low as upgrade talk meets nutrition worries

Abbott stock price steadies near a 52-week low as upgrade talk meets nutrition worries

Abbott Laboratories shares rose 0.3% to $106.34 Thursday after a broker upgrade, following sharp losses from missed revenue and a cautious outlook last week. The stock touched a 52-week low of $105.27. Abbott plans to acquire Exact Sciences for $105 per share, with a shareholder vote set for Feb. 20. The company declared a $0.63 quarterly dividend, payable Feb. 13.
29 January 2026
··
Abbott stock today: ABT rises as Exact Sciences deal filing and Volt AFib device stay in focus

Abbott stock today: ABT rises as Exact Sciences deal filing and Volt AFib device stay in focus

Abbott shares closed up 0.97% at $125.78 Tuesday, holding steady after hours. Exact Sciences, which Abbott plans to acquire for up to $23 billion, disclosed accelerated executive payouts to address “golden parachute” tax rules. Investors are tracking Abbott’s Volt device rollout and a recent FDA alert on its diabetes sensors. U.S. stocks ended lower in thin holiday trading.
31 December 2025
·
Exact Sciences (EXAS) Stock: Abbott’s $23 Billion Deal, Q3 Earnings Beat and What Investors Should Watch Now

Exact Sciences (EXAS) Stock: Abbott’s $23 Billion Deal, Q3 Earnings Beat and What Investors Should Watch Now

Abbott Laboratories has agreed to acquire Exact Sciences for $105 per share in cash, valuing the deal at up to $23 billion including debt. Exact Sciences stock traded at $101.27 mid-day December 1, near its all-time high after a 56% surge in November. The transaction is expected to close in Q2 2026, pending approvals. The offer represents a 22% premium to Exact’s pre-deal price.
1 December 2025
··
Exact Sciences (EXAS) Stock Today: Analyst Downgrades, Abbott’s $21 Billion Takeover and Legal Scrutiny – 25 November 2025

Exact Sciences (EXAS) Stock Today: Analyst Downgrades, Abbott’s $21 Billion Takeover and Legal Scrutiny – 25 November 2025

Exact Sciences shares traded near $101 on Nov. 25, just below their all-time high, after Abbott’s $21 billion takeover offer at $105 per share. The stock surged 45% in a week, with Wall Street downgrading to “Hold” as merger-arb funds entered. Closing is expected in Q2 2026, pending approvals. Shareholder lawyers have begun reviewing the deal.
25 November 2025
··
Exact Sciences (EXAS) Stock Today, November 24, 2025: Abbott Buyout Spread, Analyst Downgrades and UBS Target Hike

Exact Sciences (EXAS) Stock Today, November 24, 2025: Abbott Buyout Spread, Analyst Downgrades and UBS Target Hike

Exact Sciences shares traded near $101, just below Abbott’s $105-per-share cash offer, as analysts adjusted ratings and a law firm launched a fairness probe into the deal. The stock hovered near its 52-week high, up almost 80% year-to-date. UBS and Jefferies set new $105 targets, while Benchmark and Leerink downgraded the stock. Market cap stood at about $19.1 billion.
24 November 2025
··
Abbott Laboratories (ABT) to Buy Exact Sciences in Up to $23 Billion Cancer Diagnostics Deal – All the Key News on November 20, 2025

Abbott Laboratories (ABT) to Buy Exact Sciences in Up to $23 Billion Cancer Diagnostics Deal – All the Key News on November 20, 2025

Abbott Laboratories announced a deal to acquire Exact Sciences for $105 per share in cash, valuing the company at about $21 billion in equity and $23 billion including debt. The boards of both companies approved the transaction, which is expected to close in Q2 2026 pending regulatory and shareholder approval. Exact Sciences stock surged, while Abbott shares dipped slightly.
20 November 2025
··
Abbott to Acquire Exact Sciences for $21 Billion in Cancer Screening Mega-Deal

Abbott to Acquire Exact Sciences for $21 Billion in Cancer Screening Mega-Deal

Abbott will acquire Exact Sciences for $105 per share in cash, valuing the deal at about $23 billion including debt. The boards of both companies approved the transaction, which is set to close in the second quarter of 2026 pending shareholder and regulatory approval. Exact Sciences will become a subsidiary, expanding Abbott’s diagnostics revenue and portfolio. The offer represents a 21–22% premium to Exact’s last closing price.
20 November 2025
··
EXAS Stock Soars on Abbott Takeover Talks: Exact Sciences Jumps Over 20% on November 19, 2025

EXAS Stock Soars on Abbott Takeover Talks: Exact Sciences Jumps Over 20% on November 19, 2025

Exact Sciences shares surged as much as 28% on November 19 after reports that Abbott Laboratories is in advanced talks to acquire the company. EXAS hit a new 52-week high of $89.67 before settling near $81.79, up 17% by mid-afternoon. Trading volume exceeded 10.4 million shares, with about $645 million in stock changing hands. Negotiations could still face delays or collapse, according to sources.
19 November 2025
··
Abbott (ABT) Stock Slides on Mixed Q3 Results – Is a Rally Over?

Abbott Nears Takeover of Exact Sciences, Sending Cancer Test Maker’s Stock Soaring on November 19, 2025

Abbott Laboratories is in advanced talks to acquire Exact Sciences, sources told Bloomberg on Wednesday, in what would be Abbott’s largest deal since 2016. Exact Sciences shares surged up to 29% intraday, reaching a market value near $16 billion, while Abbott stock fell around 3%. No official comments have been made by either company.
19 November 2025
···
Go toTop